
Keywords: بوتولیسم نوزاد; botulism; cost-effectiveness; efficacy; human botulism immune globulin; infant botulism; orphan disease; orphan drug; rare diseases; BIG-IV; Human Botulism Immune Globulin Intravenous; CDPH; California Department of Public Health; FDA; US Food and Drug Ad